PT808898E - Reagente e metodo para inibicao da expressao de n-ras - Google Patents
Reagente e metodo para inibicao da expressao de n-rasInfo
- Publication number
- PT808898E PT808898E PT97107706T PT97107706T PT808898E PT 808898 E PT808898 E PT 808898E PT 97107706 T PT97107706 T PT 97107706T PT 97107706 T PT97107706 T PT 97107706T PT 808898 E PT808898 E PT 808898E
- Authority
- PT
- Portugal
- Prior art keywords
- molecules
- inhibiting
- reagent
- ras expression
- pharmaceuticals
- Prior art date
Links
- 239000003153 chemical reaction reagent Substances 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 1
- 102100039788 GTPase NRas Human genes 0.000 abstract 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000024245 cell differentiation Effects 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/121—Hammerhead
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP96108326 | 1996-05-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT808898E true PT808898E (pt) | 2004-10-29 |
Family
ID=8222818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT97107706T PT808898E (pt) | 1996-05-24 | 1997-05-12 | Reagente e metodo para inibicao da expressao de n-ras |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6037463A (pt) |
| EP (1) | EP0808898B1 (pt) |
| JP (1) | JPH1052264A (pt) |
| AT (1) | ATE267247T1 (pt) |
| CA (1) | CA2205075C (pt) |
| DE (1) | DE69729145T2 (pt) |
| DK (1) | DK0808898T3 (pt) |
| ES (1) | ES2221942T3 (pt) |
| PT (1) | PT808898E (pt) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040171031A1 (en) * | 1996-06-06 | 2004-09-02 | Baker Brenda F. | Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| US9096636B2 (en) * | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
| US20040147022A1 (en) * | 1996-06-06 | 2004-07-29 | Baker Brenda F. | 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations |
| US7812149B2 (en) * | 1996-06-06 | 2010-10-12 | Isis Pharmaceuticals, Inc. | 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations |
| US20040171030A1 (en) * | 1996-06-06 | 2004-09-02 | Baker Brenda F. | Oligomeric compounds having modified bases for binding to cytosine and uracil or thymine and their use in gene modulation |
| US20050119470A1 (en) * | 1996-06-06 | 2005-06-02 | Muthiah Manoharan | Conjugated oligomeric compounds and their use in gene modulation |
| US5898031A (en) * | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| WO2005121371A2 (en) * | 2004-06-03 | 2005-12-22 | Isis Pharmaceuticals, Inc. | Double strand compositions comprising differentially modified strands for use in gene modulation |
| FR2812945B1 (fr) * | 2000-08-10 | 2002-10-04 | Aventis Pharma Sa | Utilisation de la proteine grf1 et cellules exprimant la proteine grf1 pour le criblage de molecules |
| EP2128248B2 (en) | 2002-02-01 | 2017-01-11 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
| EP1572902B1 (en) * | 2002-02-01 | 2014-06-11 | Life Technologies Corporation | HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES |
| US20060009409A1 (en) * | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
| US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| US20040248094A1 (en) * | 2002-06-12 | 2004-12-09 | Ford Lance P. | Methods and compositions relating to labeled RNA molecules that reduce gene expression |
| US20040029275A1 (en) * | 2002-08-10 | 2004-02-12 | David Brown | Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs |
| AU2003290598A1 (en) * | 2002-11-05 | 2004-06-03 | Isis Pharmaceuticals, Inc. | Modified oligonucleotides for use in rna interference |
| EP1636342A4 (en) * | 2003-06-20 | 2008-10-08 | Isis Pharmaceuticals Inc | OLIGOMER COMPOUNDS FOR USE IN THE MODULATION OF GENES |
| US8569474B2 (en) * | 2004-03-09 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Double stranded constructs comprising one or more short strands hybridized to a longer strand |
| US8394947B2 (en) * | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
| US7884086B2 (en) * | 2004-09-08 | 2011-02-08 | Isis Pharmaceuticals, Inc. | Conjugates for use in hepatocyte free uptake assays |
| CN101970012A (zh) | 2007-09-14 | 2011-02-09 | 日东电工株式会社 | 药物载体 |
| WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4871838A (en) * | 1985-07-23 | 1989-10-03 | The Board Of Rijks Universiteit Leiden | Probes and methods for detecting activated ras oncogenes |
| WO1991018913A1 (en) * | 1990-06-07 | 1991-12-12 | City Of Hope | Ribozyme mediated reversal of transformation by cleavage of the hras oncogene rna |
| WO1991018625A1 (en) * | 1990-06-07 | 1991-12-12 | City Of Hope | Ribozyme mediated reversal of transformation by cleavage of the hras oncogene rna |
| DE552178T1 (de) * | 1990-10-12 | 1994-02-03 | Max Planck Gesellschaft | Abgeänderte ribozyme. |
| KR930016437A (ko) * | 1992-01-22 | 1993-08-26 | 귀틀라인, 슈미트 | 올리고뉴클레오티드 유사체, 이의 제조방법 및 용도 |
| WO1993023057A1 (en) * | 1992-05-14 | 1993-11-25 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting cancer development |
| EP0593901B2 (de) * | 1992-09-24 | 2008-04-09 | Sanofi-Aventis Deutschland GmbH | Oligoribonucleotid- und Ribozym-Analoga mit terminalen 3'-3'-bzw.5'-5'-Verknüpfungen |
| DE4408528A1 (de) * | 1994-03-14 | 1995-09-28 | Hoechst Ag | Peptid-Oligonucleotid-Derivate, deren Herstellung und Verwendung |
-
1997
- 1997-05-12 DE DE69729145T patent/DE69729145T2/de not_active Expired - Lifetime
- 1997-05-12 DK DK97107706T patent/DK0808898T3/da active
- 1997-05-12 AT AT97107706T patent/ATE267247T1/de active
- 1997-05-12 EP EP97107706A patent/EP0808898B1/en not_active Expired - Lifetime
- 1997-05-12 ES ES97107706T patent/ES2221942T3/es not_active Expired - Lifetime
- 1997-05-12 PT PT97107706T patent/PT808898E/pt unknown
- 1997-05-23 US US08/862,270 patent/US6037463A/en not_active Expired - Lifetime
- 1997-05-23 CA CA2205075A patent/CA2205075C/en not_active Expired - Fee Related
- 1997-05-26 JP JP9135421A patent/JPH1052264A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US6037463A (en) | 2000-03-14 |
| DE69729145D1 (de) | 2004-06-24 |
| ES2221942T3 (es) | 2005-01-16 |
| EP0808898A1 (en) | 1997-11-26 |
| CA2205075A1 (en) | 1997-11-24 |
| DK0808898T3 (da) | 2004-09-27 |
| CA2205075C (en) | 2011-08-09 |
| DE69729145T2 (de) | 2005-06-09 |
| ATE267247T1 (de) | 2004-06-15 |
| EP0808898B1 (en) | 2004-05-19 |
| JPH1052264A (ja) | 1998-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT808898E (pt) | Reagente e metodo para inibicao da expressao de n-ras | |
| BR9908280A (pt) | Inibidores de enzimas de fosfolipase | |
| DE69528470D1 (de) | Thienopyridin und thienopyrimidinderivate und ihre verwendung als entzündungshemmende mittel | |
| AU3142597A (en) | Dha-pharmaceutical agent conjugates | |
| IL109780A0 (en) | Saccharin derivative proteolytic enzyme inhibitors, their preparation and pharmaceutical compositions containing them | |
| BR0312421A (pt) | Uso de inibidores de cept e opcionalmente inibidores hmg coa redutase e/ou agentes anti-hipertensivos | |
| PL332078A1 (en) | Highly selective inhibitors of butyrylcholinesterase for trating and diagnosing the alzheimer disease and dementia | |
| BRPI0015533B8 (pt) | enzima alfa-l-iduronidase humana recombinante, composição farmacêutica compreendendo a mesma e método para sua purificação | |
| BR9713186A (pt) | Inibidores de metaloprotease 1,3-diheterocìclicos | |
| MX9702204A (es) | Tratamiento con ribozimas de enfermedades o condiciones relacionadas con niveles de lipoproteina (a) [lp(a)] en plasma, inhibiendo apolipoproteina (a) [apo(a)]. | |
| AU1430097A (en) | Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules | |
| TW225532B (pt) | ||
| BR9714631A (pt) | Método para tratar terapeuticamente olhos de mamìferos e medicamento antiinfeccioso de iodo não-irritante, oftálmico | |
| MX9704030A (es) | 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos. | |
| WO1998032846A3 (en) | Enzymatic nucleic acid treatment of diseases or conditions related to levels of c-fos | |
| AU3530999A (en) | Monomer protein with bone morphogenetic activity and medicinal agent containing the same for preventing and treating diseases of cartilage and bone | |
| NO924309L (no) | Sammensetninger og fremgangsmaater for modulering av rna-aktiviteter gjennom modifikasjon av 5' cap-strukturen til rna | |
| ES2187648T3 (es) | Metodo para la administracion de farmacos para terapia genica. | |
| AU8243198A (en) | Remedies for solid tumor containing wilms' tumor gene (wt1) expression inhibitors | |
| ATE225171T1 (de) | Aminosäurederivate zur behandlung von schlaganfall | |
| BR9814188A (pt) | "agonistas de 5-ht1f" | |
| AP2000001937A0 (en) | Method for identifying chemical active agents and active agents for inhibiting the 1-desoxy-d-xylulose-5-phosphate biosynthetic pathway. | |
| BR9810481A (pt) | Processo para preparação de 1h-indol-3-glioxamidas 4-substituìdas. | |
| ES2137665T3 (es) | Nuevos derivados de piridina o piridazina, procedimientos para su preparacion, y medicamentos que contienen estos compuestos. | |
| ID20165A (id) | Penggunaan asam 2-(3,4-dimetoksisinamoil)aminobenzoat untuk pembuatan obat untuk pengobatan atau pencegahan restenosis |